T2 Biosystems' stock extends losing streak despite FDA approval for biothreat test

Shares of T2 Biosystems extended their losing streak to two days Wednesday.

Related Keywords

,Biosystems Inc ,Article Normal ,Anthrax ,Typhus ,Plague ,Fda ,Medical Equipment Supplies ,Healthcare Life Sciences ,Medical Diagnostic Equipment Supplies ,Medical Devices Apparatus ,Diagnostic Therapeutic Devices ,Regulation Government Policy ,Financial Performance ,Share Price Movement Disruptions ,Ownership Changes ,Acquisitions Mergers Shareholdings ,New Products Services ,Corporate Actions ,Product Service Approvals ,Corporate Industrial News ,Divestments ,Products Services ,Political General News ,Health ,Medical Conditions ,Vector Borne Zoonotic Diseases ,Infectious Diseases ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,C Amp Ampe Industry News Filter ,T2 Biosystems Inc ,Tattoo ,Regulation ,Government Policy ,Share Price Movement ,Disruptions ,Acquisitions ,Mergers ,Shareholdings ,New Products ,Services ,Product ,Service Approvals ,Corporate ,Industrial News ,Products ,Political ,General News ,Vector Borne ,Zoonotic Diseases ,Medical Equipment ,Supplies ,Healthcare ,Life Sciences ,Medical Diagnostic Equipment ,Medical Devices ,Apparatus ,Diagnostic ,Therapeutic Devices ,